Form 4: Oruka Therapeutics CMO Executes Stock Option Plan

Chief Medical Officer Joana Goncalves exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Summary

• Chief Medical Officer Joana Goncalves exercised options to acquire 7,000 shares of common stock at prices of $6.84 and $7.80.
• Following the exercise, the reporting person sold a total of 7,000 shares in multiple transactions.
• The sales were executed at weighted average prices ranging from $61.56 to $63.52 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 19, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were conducted under a pre-established 10b5-1 plan and represent routine executive financial management.

Positives

• The executive maintains a significant remaining beneficial ownership of 33,377 shares of common stock.
• The transactions were executed under a pre-planned Rule 10b5-1 trading plan, indicating systematic rather than reactive selling.

Negatives

• The transaction represents a divestment of equity by a key member of the executive leadership team.

Risks

• Future share price volatility could impact the value of remaining unvested derivative securities.
• Reliance on Rule 10b5-1 plans does not eliminate the potential for negative market perception regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing; the document is limited to disclosure of insider equity transactions.

Industry Context

StockSavvy.ai notes that insider selling via Rule 10b5-1 plans is a standard practice for executives to manage personal liquidity and diversify portfolios, and is generally viewed as neutral by the market when pre-planned.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is consistent with standard corporate governance practices for executives in the biotechnology sector.
• The volume of shares sold is relatively small compared to the total holdings of the executive, which is typical for routine equity management.

Stakeholder Impact

• Shareholders should note the systematic divestment by the CMO, though it is mitigated by the use of a pre-planned trading arrangement.

Next Steps

• Continued vesting of remaining employee stock options and warrants as per the established schedule.

Key Dates

Keywords

Oruka Therapeutics, ORKA, Insider Trading, Form 4, Chief Medical Officer, Equity Compensation